Difference between revisions of "Work Product for Review"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
| − | ==Public Comment on QIBA Profiles and Protocols | + | ==Public Comment on QIBA Profiles and Protocols== |
| − | QIBA | + | QIBA documents are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details. |
| − | The [[Committees|QIBA Biomarker Committees]] | + | The [[Committees|QIBA Biomarker Committees]] consider all comments submitted, and where appropriate, post responses. |
| − | == | + | ==Comment Submission== |
| − | + | * Visit the [https://fs22.formsite.com/QIBA/QIBA_Public_Comment_Form/index.html QIBA Public Comment Webform]. | |
| + | :* Select the document you are commenting on from the dropdown menu | ||
| + | :* Provide your name or initials | ||
| + | :* Follow the other instructions on the page | ||
| + | * e-mail ([mailto:sweinmann@rsna.org Susan Weinmann]) with ''general comments'' about the Profile/Protocol concept, structure, process, etc. | ||
| − | |||
| − | + | ==QIBA Profiles and Protocols for Reference== | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: <big><font color=red> QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016</font></big>]] ''The Public Comment period ends February 1, 2017.'' | *[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: <big><font color=red> QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016</font></big>]] ''The Public Comment period ends February 1, 2017.'' | ||
Revision as of 22:01, 9 February 2017
Public Comment on QIBA Profiles and Protocols
QIBA documents are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details.
The QIBA Biomarker Committees consider all comments submitted, and where appropriate, post responses.
Comment Submission
- Visit the QIBA Public Comment Webform.
- Select the document you are commenting on from the dropdown menu
- Provide your name or initials
- Follow the other instructions on the page
- e-mail (Susan Weinmann) with general comments about the Profile/Protocol concept, structure, process, etc.
QIBA Profiles and Protocols for Reference
- QIBA Profile: QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016 The Public Comment period ends February 1, 2017.
- QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016 The Public Comment period has closed
- QIBA Spreadsheet: Small Nodule Profile References_Accuracy. Version for Public Comment. June 1, 2016 The Public Comment period has closed
- QIBA Spreadsheet: Small Nodule Profile References_Precision. Version for Public Comment. June 1, 2016 The Public Comment period has closed